ArticleInvestigational new drugs2018

Phase I dose-escalation trial of afatinib, an irreversible ErbB family blocker, in combination with gemcitabine or docetaxel in patients with relapsed or refractory solid tumors.

Sandrine Hiret et al.PubMed ↗Publisher ↗

No numbers read from the abstract.